Inspection Delays Remain For Novel Approvals By US FDA; Will Quality Office Help?
Executive Summary
Final assessment of the PDUFA V new drug review 'Program' flagged inspection delays as a continued sticking point for on-time approvals. US FDA says consolidation of manufacturing oversight under the agency’s new quality office will help.